Schizophrenia

A panel of experts in psychiatric treatment review the burden schizophrenia has on the health care system.

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, explain how to increase patient adherence to treatment and address the stigma associated with schizophrenia even in the family of the patient.

Henry Nasrallah, MD, examines schizophrenia relapse, specifically how to diagnose and prevent it before further damage has transpired in the patient’s brain.  

Rahn Bailey, MD, DFAPA, and Henry Nasrallah, MD, discuss the challenges and unmet needs psychiatrists and their teams face when treating patients with schizophrenia and their multiple comorbidities.

Joe Avelino, RN, BSN, MHSA, CPHQ, and Henry Nasrallah, MD, review schizophrenia and the needs of these patients.

Researchers find higher neurocognitive abilities are associated with an improvement of everyday life.

A higher percentage of patients suffering from a severe mental disorder such as schizophrenia or bipolar disorder, died from a COVID-19 infection than the control group.

Individuals diagnosed with mood or anxiety disorders were not linked to higher COVID-19 mortality.

Experts expect more individuals to face mental health challenges caused by the events of 2020.

Repeated Transcranial Magnetic Stimulation shows more efficacy treating bipolar disorder than schizophrenia.

The lipid profile changes were not significant after 6 months, while the changes in the lipid profile are due to other factors and not the drugs.

The first-line atypical antipsychotic was linked to better outcomes in patients than comparators aripiprazole and olanzapine.

The agency did not find any efficacy or safety issues regarding the potential treatment for adults with schizophrenia or bipolar I disorder.

The schizophrenia drug currently has a PDUFA date set for November 15.

Tardive dyskinesia at treatment onset was the strongest predictor of schizophrenia relapse.

Telemedicine could be something that is still used, even after the COVID-19 pandemic is over.

An expert discusses ALKS 3831, a potential new treatment that demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

The potential new treatment has demonstrated reduced weight gain in patients with schizophrenia compared to olanzapine.

Genetic and environmental liability were linked to poorer mental health in a cohort of more than 6000 individuals based in the Netherlands.

The number needed to treat to prevent at least 1 additional hospitalization was 7 individuals treated with aripiprazole once monthly compared with clinician’s choice.

The earliest time point where a treatment outcome could be observed was 1 week after initiation of medication compared to placebo.

More prospective studies are needed to examine how different drugs can be effective for schizophrenia patients based on the cluster of symptoms.